Blood Cancer Journal · 2021 · 99 citations · 39 references
MedicineHematologyMolecular GeneticsCancer GeneticsMolecular OncologyOncogenesCancer CytogeneticsChromosomal TranslocationsHematologic Malignancy TherapyOncogene AmplificationOncogene MutationsRas Family OncogenesAcute Myeloid Leukemia TherapyGenomic RearrangementsLeukemia CytogeneticsPrognostic PredictionPrognostic VariablesRelapsed Acute Myeloid LeukemiaTranslocation-associated LeukemiasTranslocations
Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various translocations causing KMT2Ar are conflicting. Less is known about associated mutations and their prognostic impact. In a retrospective analysis, we identified 172 adult patients with KMT2Ar AML and compared them to 522 age-matched patients with diploid AML. KMT2Ar AML had fewer mutations, most commonly affecting RAS and FLT3 without significant impact on prognosis, except for patients with ≥2 mutations with lower overall survival (OS). KMT2Ar AML had worse outcomes compared with diploid AML when newly diagnosed and at relapse, especially following second salvage (median OS of 2.4 vs 4.8 months, P < 0.0001). Therapy-related KMT2Ar AML (t-AML) had worse outcomes compared with de novo KMT2Ar AML (median OS of 0.7 years vs 1.4 years, P < 0.0001). Allogeneic hematopoietic stem cell transplant (allo-HSCT) in first remission was associated with improved OS (5-year, 52 vs 14% for no allo-HSCT, P < 0.0001). In a multivariate analysis, translocation subtypes causing KMT2Ar did not predict survival, unlike age and allo-HSCT. In conclusion, KMT2Ar was associated with adverse outcomes regardless of translocation subtype. Therefore, AML risk stratification guidelines should include all KMT2Ar as adverse.
39
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick et al. · New England Journal of Medicine · 2014 · 4.7K citations · Full text
Life Sciences, Genetics, Hematology +17
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.4K citations · Full text
Life Sciences, Genetics, Oncology +14
Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations
Medicine, Hematology, Oncology +17